Use of and Association between Heart Failure Pharmacological Treatments and Outcomes in Obese vs. non-Obese Patients with Heart Failure with Reduced Ejection Fraction: Data from the Swedish Heart Failure Registry.
Chiara CappellettoDavide StolfoNicola OrsiniLina BensonDaniele RodolicoGiuseppe M C RosanoUlf DahlströmGianfranco SinagraLars H LundGianluigi SavaresePublished in: European journal of heart failure (2023)
Obese patients were more likely to receive optimal treatments after adjustment for factors affecting tolerability, suggesting that perceived beyond actual tolerance issues limits GDMT implementation. RASi/ARNi and beta-blockers were associated with lower mortality regardless of obesity, with a greater association between RASi/ARNi and lower CVD in obese vs. non-obese patients when considering competing risk. This article is protected by copyright. All rights reserved.
Keyphrases
- obese patients
- bariatric surgery
- heart failure
- weight loss
- roux en y gastric bypass
- gastric bypass
- metabolic syndrome
- primary care
- type diabetes
- insulin resistance
- healthcare
- left ventricular
- atrial fibrillation
- physical activity
- cardiac resynchronization therapy
- mental health
- social support
- open label
- risk factors
- electronic health record
- clinical trial
- randomized controlled trial
- quality improvement
- big data
- cardiovascular disease
- coronary artery disease
- machine learning
- body mass index
- double blind
- angiotensin converting enzyme
- placebo controlled